Hoth Therapeutics Inc
HOTH
Get informed when a big investor buys or sells
+ FollowMarket Cap$10.62M
Close$
$0.45
43.6% downside
Current Fair Value
43.6% downsideOvervalued by 43.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $10.62 Million |
|---|---|
| Enterprise Value | $2.73 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.9 |
| Beta | 0.53 |
| Outstanding Shares | 20,547,977 |
Return
| Return on Equity | -162.43% |
|---|---|
| Return on Assets | -138.98% |
| Return on Invested Capital | -160.57% |
Valuation & Multiples
| P/E Ratio | -0.92 |
|---|---|
| PEG | -1.24 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.21 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
June 3, 2026
EPS Estimate
$-0.14
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
September 2, 2026
EPS Estimate
$-0.14
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 4.98%▼ 1.38% |
|---|---|
| Total Invested | $661,249▼ 33.19% |
| Investors Holding | 19▼ 3.00% |
ESG Score
No data
About Hoth Therapeutics Inc
Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. Hoth's pipeline has the potential to improve the quality of life for patients suffering fr...